ArticleDrug safety2019

Comment on 'Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017'.

Philip Schaffalitzky de Muckadell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.